<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-12-03 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-12-03/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-12-03"><meta property="og:description" content="ğŸ“… Daily Report - 2025-12-03 ä»Šæ—¥ç­›é€‰å‡º 88 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-12-03T00:00:00+00:00"><meta property="article:modified_time" content="2025-12-03T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week492025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-12-03"><meta itemprop=description content="ğŸ“… Daily Report - 2025-12-03 ä»Šæ—¥ç­›é€‰å‡º 88 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-12-03T00:00:00+00:00"><meta itemprop=dateModified content="2025-12-03T00:00:00+00:00"><meta itemprop=wordCount content="3370"><meta itemprop=keywords content="Research,Daily,Week492025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-12-03"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-12-03 ä»Šæ—¥ç­›é€‰å‡º 88 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-03</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-12-03T00:00:00Z>2025-12-03</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-12-03>ğŸ“… Daily Report - 2025-12-03</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>88</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
KMT2Dåœ¨å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œï¼ˆCRPCï¼‰ä¸­ä»‹å¯¼è°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”ï¼Œæ­ç¤ºäº†å…¶ä½œä¸ºå…³é”®è°ƒæ§å› å­çš„æ–°ä½œç”¨ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li><strong>è‚¿ç˜¤å…ç–«ä¸æ²»ç–—</strong>ï¼šåˆæˆé½å¢©æœçƒ·ä¸‰èœç±»åŒ–åˆç‰©é€šè¿‡è¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œæœ‰æ•ˆæŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ï¼Œä¸”ä¸ä¾èµ–äºKEAP1çªå˜çŠ¶æ€ã€‚</li><li><strong>åŸºå› è°ƒæ§ä¸ç–¾ç—…</strong>ï¼šKMT2Dé€šè¿‡å½±å“CRPCçš„è°±ç³»å¯å¡‘æ€§åŠå¯¹æ²»ç–—çš„ååº”ï¼›CBLåŸºå› ç¼ºé™·å½±å“Bç»†èƒå‘è‚²ä¸åŠŸèƒ½ï¼›NKX2-1è½¬å½•å› å­ä¸RUNX1ååŒä¿æŠ¤T-ALLç»†èƒå…å—DNAæŸä¼¤ã€‚</li><li><strong>ç¥ç»é€€è¡Œæ€§ç–¾ç—…</strong>ï¼šçº¿ç²’ä½“DNAè€—ç«­çš„ç¥ç»å…ƒç»†èƒè½¬å½•ç»„å­¦å˜åŒ–æ­ç¤ºä¸é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çš„é€šè·¯æ”¹å˜ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li><strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆChIP-seqã€ATAC-seqå’ŒBulk RNA-seqç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æCRPCä¸­KMT2Dçš„åŠŸèƒ½æœºåˆ¶ã€‚</li><li><strong>å•ç»†èƒæµ‹åº</strong>ï¼šåº”ç”¨äºæ¯›ç»†èƒç™½è¡€ç—…ã€é»‘è‰²ç´ ç˜¤æ·‹å·´ç»“åŠçŒªè„‚è‚ªç»„ç»‡ï¼Œæä¾›é«˜åˆ†è¾¨ç‡çš„ç»†èƒå¼‚è´¨æ€§ä¿¡æ¯ã€‚</li></ul><h3 id=-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
é¦–æ¬¡é˜æ˜ç»å¯¹æ·‹å·´ç»†èƒï¼ˆALCï¼‰è®¡æ•°å‡é«˜ä¸æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ï¼ˆCLLï¼‰çš„ç»å¯¹é£é™©å…³ç³»ï¼Œå¹¶æå‡ºæ–°å‹åŸºå› ç»„æ£€æµ‹HER2DXæ”¯æŒHER2é˜³æ€§ä¹³è…ºç™Œæ²»ç–—å†³ç­–ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è¯„ä¼°ALCè®¡æ•°ã€å¹´é¾„ã€æ€§åˆ«å¯¹CLLç»å¯¹é£é™©çš„å½±å“ã€‚</li><li>æ¢ç©¶HER2DXåŸºå› ç»„æ£€æµ‹ä¸HER2é˜³æ€§ä¹³è…ºç™Œç”Ÿç‰©å­¦ç‰¹å¾åŠæ–°è¾…åŠ©æ²»ç–—ååº”çš„å…³ç³»ã€‚</li><li>è¯„ä¼°PIK3CAçªå˜HER2é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œä¸€çº¿æ²»ç–—åï¼Œipatasertibè”åˆåŒé‡æŠ—HER2ç»´æŒæ²»ç–—çš„å®‰å…¨æ€§ä¸å¯è¡Œæ€§ã€‚</li><li>ç ”ç©¶çº¦ç¿°é€Šä¹³é…¸æ†èŒå¦‚ä½•åˆ©ç”¨èƒ†æ±é…¸å’Œæ´»æ€§æ°§æŠ‘åˆ¶é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ç»“ç›´è‚ ç™Œã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>åˆ©ç”¨è‹±å›½ç”Ÿç‰©æ ·æœ¬åº“å¤§è§„æ¨¡çºµå‘æ•°æ®è¿›è¡ŒCLLé£é™©åˆ†æã€‚</li><li>éªŒè¯HER2DXåŸºå› ç»„æ£€æµ‹åœ¨HER2é˜³æ€§ä¹³è…ºç™Œæ²»ç–—å†³ç­–ä¸­çš„åº”ç”¨ã€‚</li><li>1bæœŸä¸´åºŠè¯•éªŒè¯„ä¼°æ–°å‹AKTæŠ‘åˆ¶å‰‚ipatasertibçš„è”åˆæ²»ç–—æ–¹æ¡ˆã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
RNAæµ‹åºæ­ç¤ºä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿ã€å…ç–«æ´»æ€§ç›¸å…³ï¼Œä¸ºè‚¿ç˜¤å¾®ç¯å¢ƒç ”ç©¶æä¾›æ–°è§†è§’ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è¯„ä¼°ä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§</li><li>æ¢ç´¢è‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿ã€å…ç–«æ´»æ€§çš„å…³è”</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>åº”ç”¨RNAæµ‹åºæŠ€æœ¯åˆ†æè‚¿ç˜¤æ ·æœ¬</li></ul><p><strong>ç²¾ç‚¼æ€»ç»“</strong>ï¼š
ä»Šæ—¥åšå®¢æ›´æ–°èšç„¦äºä¸€é¡¹åˆ©ç”¨RNAæµ‹åºæŠ€æœ¯è¯„ä¼°ä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§çš„ç ”ç©¶ã€‚è¯¥ç ”ç©¶æ­ç¤ºäº†è‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿å’Œå…ç–«æ´»æ€§ä¹‹é—´å­˜åœ¨é‡è¦å…³è”ï¼Œä¸ºç†è§£è‚¿ç˜¤å¾®ç¯å¢ƒçš„å¤æ‚æ€§æä¾›äº†æ–°çš„è¯æ®ã€‚å°½ç®¡åœ¨é¢„æµ‹æ²»ç–—ååº”æ–¹é¢èƒ½åŠ›æœ‰é™ï¼Œä½†è¿™é¡¹å·¥ä½œé€šè¿‡ç²¾ç¡®çš„åˆ†å­è¡¨å¾ï¼Œä¸ºæœªæ¥æ›´æ·±å…¥åœ°ç ”ç©¶è‚¿ç˜¤å¼‚è´¨æ€§åŠå…¶å¯¹ç™Œç—‡å‘å±•çš„å½±å“å¥ å®šäº†åŸºç¡€ã€‚</p><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (83æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE309664 çº¿ç²’ä½“DNAè€—ç«­ç¥ç»å…ƒç»†èƒçš„å…¨å±€è½¬å½•ç»„å˜åŒ–æ­ç¤ºäº†é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³é€šè·¯çš„å˜åŒ–</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€Neuronalã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Blaise W Menta ; Emily Schueddig ; Amol Ranjan ; Yanming Li ; Heather M Wilkins ; Dong Pei ; Russell H SwerdlowSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground: Mitochondrial dysfunction, a prominent feature of Alzheimerâ€™s disease (AD), could represent a cause or consequence of the disease. Objective: We determined the extent to which mitochondrial dysfunction due to mitochondrial DNA (mtDNA) depletion induces transcription changes that link to AD phenomena. Methods: We performed a transcriptomic survey of human neuronal SH SY5Y and NTERA 2/NT2 mtDNA-depleted (Ï0) and intact (Ï+) cell lines. Differentially expressed genes (DEGs) between SH-SY5Y or NT2 Ï0 and Ï+ cells were identified using edgeR, and we used the Equivalent Change Index (ECI) approach to quantify concordant DEG behavior across the cell lines. Gene set enrichment and over representation analysis (GSEA; ORA) were used to determine impact on the KEGG Alzheimerâ€™s and other neurodegenerative disease pathways, ascertain pathway and term enrichment in the Reactome and Gene Ontology databases, and generate activation z-scores in the Ingenuity Pathway Analysis (IPA) database. Results: Relative to their Ï+ comparators, Ï0 lines differentially expressed >75% of their genes, and >20% more than doubled or halved expression. The KEGG Alzheimerâ€™s pathway was significantly enriched, and ECI-identified genes ranked the Alzheimerâ€™s, Parkinsonâ€™s, ALS, and Huntingtonâ€™s KEGG pathways among the most enriched gene sets. There was broad enrichment of pathways and terms relating to AD phenomena, which reflected lipid, insulin signaling, inflammation/immune response, synapse, endosome/endocytosis, RNA, and proteostasis biology. Conclusion: In neuronal cell lines, mitochondrial dysfunction due to mtDNA depletion alters gene expression in ways that recapitulate or predictably promote AD molecular phenomena.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309664">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE308273 åˆæˆé½å¢©æœçƒ·ä¸‰èœç±»åŒ–åˆç‰©å¯æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿å¹¶ä¿ƒè¿›æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œä¸”è¯¥ä½œç”¨ç‹¬ç«‹äºç™Œç—‡KEAP1çªå˜çŠ¶æ€</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immune</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Christopher J Occhiuto ; Jessica A Moerland ; Karen T Liby ; Ana S LealSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusKEAP1 negatively regulates the cytoprotective factor NRF2 and is commonly inactivated in lung cancer cells. Loss of function KEAP1 mutations in cancer cells contribute to NRF2 activation and tumor immune evasion through immunosuppression and drug resistance. Counterintuitively, treatment with synthetic oleanane triterpenoids, potent NRF2 activa-tors, reduces preclinical tumor burden. This suggests the functional target of these drugs in cancer models is not the cancer cells but another tumor immune microenvironment (TIME) cell population. The anti-tumor potential of cells within the TIME, particularly macrophages, is potentiated by triterpenoid treatment in cancers with wild-type KEAP1 status. As KEAP1-mutant cancers show reduced tumor immune responses, triterpenoid-mediated immune stimulation may particularly benefit these cases, but this has not been investigated. To characterize the immunomodulatory effects of triterpenoids in KEAP1-mutant lung cancer, we studied tumor-educated bone marrow-derived macrophages (TE-BMDMs) and lung cancer models treated with the triterpenoids CDDO-Me or omaveloxolone. RNA-sequencing of TE-BMDMs cultured in KEAP1 KO compared to WT cancer-conditioned media had enhanced tumor-promoting phenotypes which reversed with CDDO-Me treatment. Similarly, subcutaneous KEAP1 KO tumors were larger and more immune-suppressed compared to WT tumors. Both CDDO-Me and omaveloxolone reduced tumor burden and improved immune cell phenotypes within the TIME, independent of KEAP1 mutational status.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308273">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE308945 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [FOSL1 ChIP-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308945">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE296116 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA3 Bulk RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296116">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE296115 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [LNCaP Bulk RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296115">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE293211 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA2 Bulk RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Wanlu ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293211">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE293202 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [H3K4me2 ChIP-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293202">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>GSE293182 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [PC3 Bulk RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293182">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>GSE293140 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [PC3 Bulk ATAC-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293140">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> â­ <strong>GSE293101 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [KMT2D ChIP-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293101">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 73 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨4æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4><p><strong>1.</strong> <strong>æ·‹å·´ç»†èƒè®¡æ•°åŠæ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…é£é™©ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ ç»å¯¹æ·‹å·´ç»†èƒï¼ˆALCï¼‰è®¡æ•°å‡é«˜å¸¸è¢«ç”¨ä½œæ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ï¼ˆCLLï¼‰è¯Šæ–­æ£€æŸ¥çš„é¦–è¦æŒ‡æ ‡ã€‚CLL çš„ç»å¯¹é£é™©ä¸å¹´é¾„ã€æ€§åˆ«å’Œ ALC çš„å…³ç³»å°šæœªè¢«æè¿°ã€‚æ–¹æ³• æˆ‘ä»¬ä½¿ç”¨äº†æ¥è‡ªè‹±å›½ç”Ÿç‰©æ ·æœ¬åº“çš„ 475,399 åçºµå‘éšè®¿ç ”ç©¶å‚ä¸è€…çš„è¯Šæ–­å‰ ALC ä¿¡æ¯ï¼Œä¸­ä½éšè®¿ 11.6 å¹´ï¼Œå…¶ä¸­ 854 åå‚ä¸è€…è¢«è¯Šæ–­ä¸º CLLã€‚åŸºäºæ€§åˆ«ã€æ‹›å‹Ÿå¹´é¾„å’Œè¯Šæ–­å‰ ALC çš„çµæ´»å‚æ•°ç”Ÿå­˜æ¨¡å‹ï¼Œå»ºç«‹äº† CLL é£é™©æ¨¡å‹ã€‚ç»“æœä¸ ALC ä½äº 2 x109 ç»†èƒ/å‡çš„ç ”ç©¶å‚ä¸è€…ç›¸æ¯”ï¼ŒALC ç»†èƒæ•°ä¸º 3 è‡³ 4x109 ç»†èƒ/å‡çš„æ‚£è€…ï¼ŒCLL é£é™©å‡ ä¹é«˜å‡º 8 å€ï¼ˆå¿ƒç‡ 7.76,95%ç½®ä¿¡åŒºé—´ï¼š6.24-9.65ï¼‰ã€‚ç”·æ€§çš„ CLL ç»å¯¹é£é™©æ˜¯å¥³æ€§çš„ä¸¤å€ã€‚å¯¹äº 60 å² ALC ä¸º 5x109 ç»†èƒ/L çš„äººç¾¤ï¼Œç”·æ€§ä¼°è®¡ 10 å¹´ CLL é£é™©ä¸º 6.5%ï¼ˆ95%ç½®ä¿¡åŒºé—´ï¼š5.6%-7.5%ï¼‰ï¼Œå¥³æ€§ä¸º 3.5%ï¼ˆ3.0%-4</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1995612811164758016/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>HER2DX åŸºå› ç»„æ£€æµ‹ä¸ HER2 é˜³æ€§ä¹³è…ºç™Œç”Ÿç‰©å­¦å’Œç—…ç†ç‰¹å¾çš„å…³è”ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ HER2DX æ˜¯ä¸€ç§ç»è¿‡éªŒè¯çš„åŸºå› ç»„æ£€æµ‹æ³•ï¼Œç”¨äºæ”¯æŒæ—©æœŸ HER2 é˜³æ€§ï¼ˆHER2+ï¼‰ä¹³è…ºç™Œçš„æ²»ç–—å†³ç­–ã€‚å®ƒæä¾›ä¸‰ä¸ªè¯„åˆ†ï¼šå¤å‘é£é™©ã€ç—…ç†å®Œå…¨ååº”ï¼ˆpCRï¼‰çš„å¯èƒ½æ€§å’Œ ERBB2 mRNA è¡¨è¾¾ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼° HER2DX ä¸ç»„ç»‡ç—…ç†ç‰¹å¾ä¹‹é—´çš„å…³è”ï¼Œå¹¶è¯„ä¼°å…¶ä¸æ–°è¾…åŠ©ç–—æ³•å pCR çš„å…³ç³»ã€‚æ–¹æ³• åœ¨è¥¿ç­ç‰™å¸¸è§„æŠ¤ç†æœŸé—´ï¼ˆ2022 å¹´ 1 æœˆè‡³ 2025 å¹´ 6 æœˆï¼‰ï¼Œæ ¹æ®ç°æœ‰ HER2DX ç»“æœåˆ†æäº†æ–°è¯Šæ–­çš„ I-III æœŸ HER2+ä¹³è…ºç™Œæ‚£è€…ã€‚é›†ä¸­ HER2DX æ£€æµ‹å¯¹å›ºå®šç¦é©¬æ—ã€çŸ³èœ¡åµŒå…¥çš„è‚¿ç˜¤æ ·æœ¬è¿›è¡Œäº†ã€‚ç»„ç»‡ç—…ç†å­¦åˆ†æåŒ…æ‹¬è‚¿ç˜¤ç­‰çº§ã€æ¿€ç´ å—ä½“ï¼ˆHRï¼‰çŠ¶æ€ã€ç»„ç»‡å­¦äºšå‹ã€Ki67 æŒ‡æ•°ã€HER2 å…ç–«ç»„åŒ–ï¼ˆIHCï¼‰è¯„åˆ†ã€é—´è´¨è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒï¼ˆTILsï¼‰ã€ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰åŠç©ºé—´å…ç–«åˆ†å¸ƒã€‚è¿›è¡Œäº†å•å˜é‡å’Œå¤šå˜é‡é€»è¾‘å›å½’åˆ†æï¼Œä»¥è¯†åˆ«æ–°è¾…åŠ©æ›²å¦¥ç å•æŠ—æ²»ç–—å pCR ç›¸å…³çš„å› ç´ ã€‚ç»“æœ å…±åˆ†æ 410</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1995612813853306880/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>åœ¨æºå¸¦ PIK3CA çªå˜çš„ HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºè‚¿ç˜¤ä¸­ï¼Œå°† ipatasertib åŠ å…¥åŒé‡æŠ— HER2 ç»´æŒæ²»ç–—ï¼š1b æœŸ SOLTI-1507 IPATHER è¯•éªŒã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ è¯„ä¼°ä¼Šå¸•æ‰˜è¥¿å¸ƒè”åˆæ›²å¦¥ç å•æŠ—å’Œæ´¾å¦¥ç¥–å•æŠ—ä½œä¸º HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…åœ¨ä¸€çº¿æ²»ç–—åç»´æŒæ²»ç–—çš„å®‰å…¨æ€§å’Œå¯è¡Œæ€§ï¼Œé€‚ç”¨äºæºå¸¦ PIK3CA çªå˜çš„ HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ã€‚å®éªŒè®¾è®¡ æœ¬å‰ç»æ€§ã€å¤šä¸­å¿ƒã€å•è‡‚ã€1b æœŸä¸´åºŠç ”ç©¶è¯„ä¼°äº† AKT æŠ‘åˆ¶å‰‚ä¼Šå¸•æ‰˜è¥¿å•æŠ—ï¼ˆipatasertibï¼‰ä¸æ›²å¦¥ç å•æŠ—ï¼ˆtrastuzumabï¼‰å’Œæ´¾å¦¥ç¥–å•æŠ—ï¼ˆHPï¼‰è”åˆä½¿ç”¨ï¼Œé…åˆæˆ–ä¸ä½¿ç”¨å†…åˆ†æ³Œæ²»ç–—ä½œä¸ºç»´æŒç–—æ³•çš„å®‰å…¨æ€§å’Œåˆæ­¥ç–—æ•ˆï¼Œé€‚ç”¨äºä¸€çº¿è¯±å¯¼åŒ–ç–—å’Œ HP åä¸å¯åˆ‡é™¤çš„å±€éƒ¨æ™šæœŸæˆ–è½¬ç§»æ€§ PIK3CAmutã€HER2 é˜³æ€§ä¹³è…ºç™Œæ‚£è€…ã€‚ç»“æœ å…±çº³å…¥ 17 ä¾‹æ‚£è€…ï¼Œ ä¸­ä½éšè®¿æ—¶é—´ä¸º 27.7 ä¸ªæœˆã€‚åœ¨å‰‚é‡é€‰æ‹©é˜¶æ®µï¼Œä¾å¸•æ‰˜æ²™æ›¿å¸ƒæ¯æ—¥ 400 æ¯«å…‹ï¼ˆ21 å¤©æœç”¨ï¼Œ7 å¤©åœè¯ï¼‰ä¸æ ‡å‡† HP å‰‚é‡è¢«ç¡®ç«‹ä¸ºæ¨èçš„ç¬¬äºŒé˜¶æ®µå‰‚é‡ï¼ˆRP2Dï¼‰ã€‚è¿™ä¸€å†³å®šåŸºäºåœ¨åˆå§‹ 28 å¤©å‘¨æœŸå†…ï¼Œå‰å…­åæ¥å—è¯¥å‰‚é‡æ²»ç–—çš„æ‚£è€…å‡æœªå‡ºç°å‰‚é‡é™åˆ¶æ€§æ¯’æ€§ï¼Œè¯¥ä¸ºä¸»è¦ç»ˆç‚¹ã€‚7</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1995612816629936128/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> <strong>è‚ é“æ£€æŸ¥ï¼šçº¦ç¿°é€Šä¹³é…¸æ†èŒåˆ©ç”¨èƒ†æ±é…¸å’Œæ´»æ€§æ°§æ¥æŠ‘åˆ¶é«˜è„‚é¥®é£Ÿå¼•èµ·çš„ç»“ç›´è‚ ç™Œã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚ é“</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç»“ç›´è‚ ç™Œæ˜¯å…¨çƒæœ€å¸¸è§ä¸”è‡´å‘½çš„æ¶æ€§è‚¿ç˜¤ä¹‹ä¸€ï¼Œå…¶å‘ç—…ç‡ä¸ç”Ÿæ´»æ–¹å¼å› ç´ å¯†åˆ‡ç›¸å…³ï¼ŒåŒ…æ‹¬é«˜è„‚é¥®é£Ÿï¼ˆHFDï¼‰ã€‚æµè¡Œç—…å­¦ç ”ç©¶å°†é«˜è„‚è‚ªé¥®é£Ÿä¸ç»“ç›´è‚ ç™Œé£é™©å¢åŠ ç›¸å…³ï¼Œä½†ä¸ªä½“æ˜“æ„Ÿæ€§å·®å¼‚å¾ˆå¤§ï¼Œæ½œåœ¨é©±åŠ¨å› ç´ ä»ä¸å……åˆ†ã€‚è¿‘æœŸè¿›å±•ä½¿ç ”ç©¶èŒƒå¼ä»ä»…å…³æ³¨é¥®é£Ÿç»„æˆè½¬å‘è€ƒè™‘å®¿ä¸»-å¾®ç”Ÿç‰©ç›¸äº’ä½œç”¨åŠå¾®ç”Ÿç‰©ä»£è°¢ç‰©è°±å¯¹é«˜è„‚è‚ªé¥®é£Ÿé©±åŠ¨ç»“ç›´è‚ ç™Œé£é™©çš„ä¸ªä½“å·®å¼‚è´¡çŒ®ã€‚åœ¨æœ¬æœŸã€Šç™Œç—‡ç ”ç©¶ã€‹æ‚å¿—ä¸­ï¼Œåˆ˜æ°åŠå…¶åŒäº‹ç ”ç©¶äº†çº¦ç¿°é€Šä¹³é…¸æ†èŒä½œä¸ºæŠ‘åˆ¶é«˜è„‚è›‹ç™½é©±åŠ¨è‚¿ç˜¤å‘ç”Ÿçš„ä¿æŠ¤æ€§ç»†èŒã€‚é€šè¿‡ä¿ƒè¿›å…±è½­èƒ†é…¸è½¬åŒ–ä¸ºé¡ºä¾¿åµè´¨èƒ†é…¸ï¼Œå¼ºæ£®æ°é•¿æ†èŒå¼•å‘çº¿ç²’ä½“åŠŸèƒ½éšœç¢ï¼Œä»è€Œä¿ƒè¿›æ´»æ€§æ°§ç‰©ç§çš„äº§ç”Ÿï¼Œå¹¶è¯±å¯¼å‡‹äº¡ä»¥æŠ‘åˆ¶ç»“ç›´è‚ ç™Œçš„å‘å±•ã€‚è¿™äº›ä¸´åºŠå‰å‘ç°ä¸ºèƒ†æ±é…¸ä»£è°¢ã€è‚ é“å¾®ç”Ÿç‰©ç¾¤ä¸è‡´ç™Œæœºåˆ¶çš„äº¤æ±‡æä¾›äº†æœºåˆ¶æ€§è§è§£ï¼Œå¹¶ä¸ºæœªæ¥åŸºäºç›Šç”ŸèŒçš„ç™Œç—‡é¢„é˜²è½¬åŒ–ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚å‚è§ Liu ç­‰äººç›¸å…³æ–‡ç« ï¼Œç¬¬ 4600 é¡µã€‚</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1995608978590117888/t>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨1æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4><p><strong>1.</strong> <strong>é€šè¿‡RNAè¡¨è¾¾äº†è§£è‚¿ç˜¤å¼‚è´¨æ€§</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumor</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing was used to evaluate tumor heterogeneity in breast cancer, revealing links to cell growth and immune activity but limited power in predicting treatment response&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/understanding-tumor-heterogeneity-through-rna-expression/>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>cancer</td><td>28</td></tr><tr><td>RNA-seq</td><td>18</td></tr><tr><td>histone</td><td>17</td></tr><tr><td>tumor</td><td>9</td></tr><tr><td>ChIP-seq</td><td>8</td></tr><tr><td>leukemia</td><td>7</td></tr><tr><td>metabolic</td><td>5</td></tr><tr><td>sequencing</td><td>5</td></tr><tr><td>single-cell</td><td>5</td></tr><tr><td>ATAC-seq</td><td>4</td></tr><tr><td>scRNA</td><td>4</td></tr><tr><td>immunity</td><td>3</td></tr><tr><td>pathway</td><td>2</td></tr><tr><td>methylation</td><td>2</td></tr><tr><td>immune</td><td>2</td></tr><tr><td>lymph</td><td>2</td></tr><tr><td>regex:lymph(o</td><td>atic)?</td></tr><tr><td>spatial</td><td>2</td></tr><tr><td>transcriptome</td><td>2</td></tr><tr><td>Alzheimer</td><td>1</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (73æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293089">GSE293089 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [FOXA1 ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293080">GSE293080 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [AR ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293079">GSE293079 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA3 Bulk ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293067">GSE293067 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [LNCAP Bulk ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293060">GSE293060 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [DU145 Bulk RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293025">GSE293025 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [DU145 Bulk ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290943">GSE290943 scRNAseq åˆ†æäº†åŸå‘æ€§é»‘è‰²ç´ ç˜¤å°é¼  BP (TyrCre-ERT2Tg/0 BrafLSL-V600E/+ Ptenlox/lox) å’Œ BPT (TyrCre-ERT2Tg/0 BrafLSL-V600E/+ Ptenlox/lox Tslp-/-) è‚¿ç˜¤å¼•æµæ·‹å·´ç»“ (tdLN) ä¸­è¿ç§»æ€§æ ‘çªçŠ¶ç»†èƒ (DC) å’Œ CD4+ T ç»†èƒçš„åˆ†å¸ƒæƒ…å†µã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311935">GSE311935 æ¯›ç»†èƒç™½è¡€ç—… (HCL) æ‚£è€…ç™Œç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311267">GSE311267 é¶å‘ Syndecan-1 çš„æ²»ç–—æ€§æŠ—ä½“æŠ‘åˆ¶å·¨èƒé¥®ä½œç”¨å¹¶è¯±å¯¼èƒ°è…ºç™Œçš„æŠ—è‚¿ç˜¤å…ç–«</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298098">GSE298098 è¯±å¯¼å‹ CD147 ä¸Šè°ƒå¢å¼ºæŒç»­æ€§ SARS-CoV-2 æ„ŸæŸ“ï¼Œå¼•å‘é‡ç—‡ COVID-19ï¼Œä¸”ä¸ ACE2 æ— å…³ [ç©ºé—´è½¬å½•ç»„å­¦]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230037">GSE230037 çŒªè„‚è‚ªç»„ç»‡çš„å•ç»†èƒè½¬å½•ç»„æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309586">GSE309586 å…¨è½¬å½•æœ¬ m6A ç”²åŸºåŒ–å½±å“ä¸ä¾èµ–å¸½ç»“æ„çš„ç¿»è¯‘èµ·å§‹ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307942">GSE307942 äººç±»ç™½ç»†èƒä¸­CBLçš„ä½“ç»†èƒç¼ºé™·ä¼šæŸå®³Bç»†èƒè€ŒéTç»†èƒçš„å‘è‚²å’ŒåŠŸèƒ½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288188">GSE288188 è½¬å½•å› å­ NKX2-1 ä¸ RUNX1 ååŒä½œç”¨ï¼Œä¿æŠ¤ T ç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ç»†èƒå…å— DNA æŸä¼¤ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288187">GSE288187 è½¬å½•å› å­ NKX2-1 ä¸ RUNX1 ååŒä½œç”¨ï¼Œä¿æŠ¤ T ç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ç»†èƒå…å— DNA æŸä¼¤ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266626">GSE266626 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308946">GSE308946 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [CUT&amp;Run]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296270">GSE296270 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶KMT2Dæ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291282">GSE291282 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶KMT2Dæ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278892">GSE278892 MC903 å¤„ç†å°é¼ çš®è‚¤å¼•æµæ·‹å·´ç»“ä¸­è¿ç§»æ€§ nLCncDC1 çš„ CITEseq</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308702">GSE308702 ARMCX3 æ•²ä½çš„è½¬å½•ç»„åˆ†ææ­ç¤ºäº†ä¹³è…ºç™Œç»†èƒä¸­ p53â€“IFIH1 è½´å’Œå…ç–«é€šè·¯çš„æ¿€æ´»ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290391">GSE290391ï¼šå°é¼ é€ è¡€å±‚çº§ç»“æ„çš„å•ç»†èƒRNAæµ‹åºã€ULACæµ‹åºå’ŒRNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311811">GSE311811 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304316">GSE304316 æ„å»ºå¹¿è—¿é¦™èƒšçŠ¶ä½“çš„å•ç»†èƒè½¬å½•ç»„å›¾è°±ï¼Œæ­ç¤º PcNAC048 ä½œä¸ºåŒé‡è°ƒæ§å› å­ï¼Œåè°ƒä¾§æ ¹å½¢æ€å‘ç”Ÿå’Œå¹¿è—¿é¦™é†‡ç”Ÿç‰©åˆæˆã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303432">GSE303432 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³• [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274326">GSE274326 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [RNA-seq PDX]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274325">GSE274325 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [RNA-seq Tumoroid]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274321">GSE274321 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310670">GSE310670 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ç¨‹åºã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310669">GSE310669 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä»è€Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ç¨‹åºã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309588">GSE309588 å…¨è½¬å½•æœ¬ m6A ç”²åŸºåŒ–å½±å“ä¸ä¾èµ–å¸½ç»“æ„çš„ç¿»è¯‘èµ·å§‹ [Ribo-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296077">GSE296077 äººç±»ç¥ç»å…ƒåˆ†åŒ–è¿‡ç¨‹ä¸­çš„ä»£è°¢é‡ç¼–ç¨‹æ­ç¤ºè°·æ°¨é…°èƒºé…¶æ˜¯è„†æ€§Xç»¼åˆå¾çš„å…³é”®å†³å®šå› ç´ </a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278790">GSE278790 PDX1 ç£·é…¸åŒ–ä»‹å¯¼èƒ°å²›Î²ç»†èƒä¸­çš„æ°¨åŸºé…¸-mTORC1 ä¿¡å·ä¼ å¯¼ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278789">GSE278789 PDX1 ç£·é…¸åŒ–ä»‹å¯¼èƒ°è…º Î² ç»†èƒä¸­çš„æ°¨åŸºé…¸-mTORC1 ä¿¡å·ä¼ å¯¼ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266625">GSE266625 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ [HiChIP]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311806">GSE311806 è†³é£Ÿç›æŸå®³ç›æ•æ„Ÿæ€§é«˜è¡€å‹æ‚£è€…çš„æ˜¼å¤œèŠ‚å¾‹ç”Ÿç†ä»£è°¢é€‚åº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304330">GSE304330 RNAæµ‹åºæ­ç¤ºäº†é“œç»¿å‡å•èƒèŒç”Ÿé•¿é˜¶æ®µç‰¹å¼‚æ€§çš„æ•´ä½“è½¬å½•ä½“æ¸©è°ƒèŠ‚å·®å¼‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304229">GSE304229 RNA-seq æ•°æ®æ¥è‡ªåœ¨ 37Â°C æˆ– 25Â°C ä¸‹åŸ¹å…»è‡³ç¨³å®šæœŸçš„ PAO1 å’Œ Î”lasR èŒæ ªã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304114">GSE304114 PAO1 åœ¨ä¸¤ç§æ¸©åº¦å’Œä¸¤ä¸ªç”Ÿé•¿é˜¶æ®µçš„ RNA-seq</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295016">GSE295016 TREM2 è¡¨è¾¾æ°´å¹³å¯¹å°èƒ¶è´¨ç»†èƒçŠ¶æ€ã€ä»£è°¢èƒ½åŠ›å’Œ TREM2 æ¿€åŠ¨å‰‚çš„åŠŸæ•ˆè‡³å…³é‡è¦ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291343">GSE291343 é›„æ€§è‚¾ä¸Šè…ºçš®è´¨ç±»å›ºé†‡ç”Ÿæˆè°±ç³»çš„å•ç»†èƒRNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284496">GSE284496 å°é¼ èƒšèƒæ™šæœŸå’Œå‡ºç”Ÿæ—©æœŸè‚¾è„çš„å•æ ¸ RNA æµ‹åºã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283722">GSE283722 SGLT2æŠ‘åˆ¶å‰‚æ©æ ¼åˆ—å‡€å¢å¼ºè‚Œçƒè›‹ç™½R403Qçªå˜è‚¥åšå‹å¿ƒè‚Œç—…å°é¼ çš„ä»£è°¢æ•ˆç‡å¹¶æ”¹å–„å·¦å¿ƒå®¤è‚¥åš</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282712">GSE282712 æ–°ç”Ÿå°é¼ è„‘å†…å…ˆå¤©æ€§å·¨ç»†èƒç—…æ¯’æ„ŸæŸ“çš„å•ç»†èƒåˆ†è¾¨ç‡åˆ†å­ç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281413">GSE281413 æ—©å‘å‹å’Œä¸­å‘å‹ç»“ç›´è‚ ç™ŒåŠå…¶åŒ¹é…çš„æ­£å¸¸ç»“è‚ ç»„ç»‡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277899">GSE277899 å¯¹æ„ŸæŸ“é¸Ÿåˆ†ææ†èŒå››å‘¨çš„é‡ç”Ÿå‹ HSCã€MPP3ã€GMP å’Œå·¨å™¬ç»†èƒè¿›è¡Œ CUT&amp;RUN æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271074">GSE271074 TREM2è¡¨è¾¾æ°´å¹³å¯¹å°èƒ¶è´¨ç»†èƒçŠ¶æ€ã€ä»£è°¢èƒ½åŠ›å’ŒTREM2æ¿€åŠ¨å‰‚çš„ç–—æ•ˆè‡³å…³é‡è¦</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311914">GSE311914ï¼šäºŒç¡«è…™å¤„ç†å°é¼ æ½˜æ°ç»†èƒåï¼Œè‚ ä¸Šçš®ç»†èƒæ¥æºçš„ç»†èƒå¤–å›Šæ³¡çš„ miRNA è¡¨è¾¾è°±åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290390">GSE290390 å°é¼ é€ è¡€å±‚çº§çš„å…¨å±€mRNAè°±åˆ†æï¼ˆRNA-seqï¼‰</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290388">GSE290388ï¼šNat10ç¼ºå¤±åå°é¼ é€ è¡€å¹²ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269664">GSE269664 ç”¨äºé¶å‘é™è§£ MYC å’Œ KRAS çš„å¼‚åŒåŠŸèƒ½è›‹ç™½æ¨¡æ‹Ÿèšåˆç‰©</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311917">GSE311917 å‡‹äº¡ç»†èƒæ¸…é™¤è§¦å‘å‰åˆ—è…ºé€€åŒ–è¿‡ç¨‹ä¸­ä¸Šçš®ç»†èƒå‘½è¿é‡ç¼–ç¨‹ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311846">GSE311846 éå°ç»†èƒè‚ºç™Œä¸­çº¿ç²’ä½“åŒé“¾RNAä¾èµ–æ€§è„‚è´¨é‡ç¼–ç¨‹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311813">GSE311813 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚[å¼‚ç§ç§»æ¤]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311810">GSE311810 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚ [CRISPR ç­›é€‰]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311794">GSE311794 è·¨è†œè›‹ç™½åŠŸèƒ½ç­›é€‰é‰´å®šå‡ºå¤šèœé†‡ç„¦ç£·é…¸ç£·é…¸é…¶ CAX-4 æ˜¯ç²—ç³™è„‰å­¢èŒä¸­éº¦è§’ç”¾é†‡ç”Ÿç‰©åˆæˆå’Œå”‘ç±»è€è¯æ€§çš„å…³é”®è°ƒæ§å› å­</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311745">GSE311745 åŸºäºç©ºé—´è½¬å½•ç»„å­¦çš„IgAè‚¾ç—…å†…æ¯›ç»†è¡€ç®¡å†…ç»†èƒå¢ç”Ÿ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311711">GSE311711 ç‰™é¾ˆæˆçº¤ç»´ç»†èƒæš´éœ²äºæ´»åŒ–è¡€å°æ¿çš„ RNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311707">GSE311707 ç¡¬åº¦ä»‹å¯¼çš„æ—åˆ†æ³Œä¿¡å·å¢å¼ºå£è…”é³çŠ¶ç»†èƒç™Œä¸­ä¸Šçš®é—´è´¨è½¬åŒ–ï¼ˆEMTï¼‰çš„è¯±å¯¼</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303442">GSE303442 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³•[å¢æ®–]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303438">GSE303438 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³• [TCR-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302983">GSE302983 é¶å‘å‰åˆ—è…ºç™Œä¸­å·²å­˜åœ¨çš„æ£’çŠ¶ç»†èƒå¯å¢å¼ºé›„æ¿€ç´ å‰¥å¤ºç–—æ³•çš„æ•ˆæœ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300781">GSE300781 C13 ç»†èŒç¾¤è½å¯¹ç©ºè‚ å¼¯æ›²èŒæ„ŸæŸ“æ•æ„Ÿï¼Œè¿™ä¼šå½±å“é¶å‘ç»†èŒå’Œå®¿ä¸»åŸºå› çš„å®¿ä¸»æ¥æº miRNAã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298097">GSE298097 è¯±å¯¼å‹ CD147 ä¸Šè°ƒå¢å¼ºæŒç»­æ€§ SARS-CoV-2 æ„ŸæŸ“ï¼Œå¼•å‘é‡ç—‡ COVID-19ï¼Œä¸”ä¸ ACE2 æ— å…³ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284367">GSE284367 æŠ‘åˆ¶æ•´åˆåº”æ¿€ååº”é€šâ€‹â€‹è¿‡ mTOR é€šè·¯ä¿ƒè¿›åŸå§‹åµæ³¡æ´»åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282999">GSE282999 æ£‰èŠ±èƒšç è¡¨çš®æ—©æœŸçº¤ç»´å‘è‚²è¿‡ç¨‹ä¸­æŸ“è‰²è´¨å¯åŠæ€§çš„å•ç»†èƒåˆ†æ [scATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274368">GSE274368 IKKa é€šè¿‡æŠ‘åˆ¶ç´§å¯†è¿æ¥ç¨³å®šå’Œç»†èƒé›†ä½“è¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§»</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273832">GSE273832 ROSæ¿€æ´»NETsé‡Šæ”¾éª¨é«“CD55+ä¸­æ€§ç²’ç»†èƒï¼Œä¿ƒè¿›éª¨éª¼æ—©æœŸè€åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271019">GSE271019 å°é¼ è„‘ä¸­çš„ RNA ä¿®é¥°ã€å¯å˜å‰ªæ¥å’Œç¯çŠ¶ RNA å›¾è°±ï¼šè‚Œè‹·åŠå…¶ä»– [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262356">GSE262356 åŒ…è£¹å“ºä¹³åŠ¨ç‰©ç»†èƒçš„å°å‹éç¼–ç RNAä¿ƒè¿›å…ˆå¤©å…ç–«</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252429">GSE252429 åŒ…è£¹å“ºä¹³åŠ¨ç‰©ç»†èƒçš„å°å‹éç¼–ç RNAä¿ƒè¿›å…ˆå¤©å…ç–«</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246570">GSE246570 è¡€çº¢ç´ åŠ æ°§é…¶-1å¯¹è‚¾è„ä¸­å¿ƒç¢³ä»£è°¢çš„æ§åˆ¶</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE195999">GSE195999 è§£å†»åéª¨é«“é—´å……è´¨å¹²ç»†èƒçš„å•ç»†èƒæµ‹åº</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-02 21:35</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week492025/ rel=tag>Week492025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-12-02/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-02</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-12-04/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-04</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-10/>ç§‘ç ”æ—¥æŠ¥ 2026-01-10</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-09/>ç§‘ç ”æ—¥æŠ¥ 2026-01-09</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-08/>ç§‘ç ”æ—¥æŠ¥ 2026-01-08</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-07/>ç§‘ç ”æ—¥æŠ¥ 2026-01-07</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-06/>ç§‘ç ”æ—¥æŠ¥ 2026-01-06</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (73)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (73)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>